uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Show others and affiliations
2012 (English)In: Investigational new drugs, ISSN 0167-6997, E-ISSN 1573-0646, Vol. 30, no 4, 1519-1530 p.Article in journal (Refereed) Published
Abstract [en]

Introduction Modeling and simulation of pharmacokinetics and pharmacodynamics has previously been shown to be potentially useful in designing Phase I programs of novel anti-cancer agents that show hematological toxicity. In this analysis, a two-stage model-based trial design was evaluated retrospectively using data from the Phase I program with the aurora kinase inhibitor barasertib. Methods Data from two Phase I trials and four regimens were used (n = 79). Using barasertib-hydroxy QPA plasma concentrations and neutrophil count data from only study 1A, a PKPD model was developed and subsequently used to predict the MTD and a safe starting dose for the other trials. Results The PKPD model based on data from the first study adequately described the time course of neutrophil count fluctuation. The two-stage model-based design provided safe starting doses for subsequent phase I trials for barasertib. Predicted safe starting dose levels were higher than those used in two subsequent trials, but lower than used in the other trial. Discussion The two-stage approach could have been applied safely to define starting doses for alternative dosing strategies with barasertib. The limited improvement in efficiency for the phase I program of barasertib may have been due to the fact that starting doses for the studied phase I trials were already nearly optimal. Conclusion Application of the two-stage model-based trial design in Phase I programs with novel anti-cancer drugs that cause haematological toxicity is feasible, safe, and may lead to a reduction in the number of patient treated at sub-therapeutic dose-levels.

Place, publisher, year, edition, pages
2012. Vol. 30, no 4, 1519-1530 p.
Keyword [en]
Barasertib, AZD1152, Oncology, Phase I, Modeling and simulation, Hematological toxicity
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-178072DOI: 10.1007/s10637-011-9694-5ISI: 000305955300026OAI: oai:DiVA.org:uu-178072DiVA: diva2:542161
Available from: 2012-07-30 Created: 2012-07-27 Last updated: 2012-07-30Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Keizer, Ron J.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Investigational new drugs
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 131 hits
ReferencesLink to record
Permanent link

Direct link